BeStock  
Stocks › Biotechnology › TYRA

TYRA BIOSCIENCES, INC. TYRA

US equityMarket cap rank #2928Biotechnology
$20.12 +$0.39 (+1.98%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $20.29 +0.84%
Open$19.62
Prev close$19.73
Day range$19.48 – $20.44
Volume467.6K
Market cap$1.39B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$54.89M-66.6% YoY
Net profit-$51.12M-71.2% YoY
Diluted EPS-$0.74-48.0% YoY
Free cash flow-$32.30M-44.1% YoY
Operating cash flow-$32.21M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-25.6MDec '24$-28.1MMar '25$-28.1MJun '25$-29.9MSep '25$-33.8MDec '25$-39.3MMar '26$-45.6MJun '26$-51.1MSep '26

Diluted EPS by quarter

-0.43Dec '24-0.47Mar '25-0.47Jun '25-0.50Sep '25-0.57Dec '25-0.64Mar '26-0.69Jun '26-0.74Sep '26

Free cash flow by quarter

$-19.6MDec '24$-25.5MMar '25$-23.7MJun '25$-22.4MSep '25$-23.7MDec '25$-32.7MMar '26$-31.1MJun '26$-32.3MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-34.9%
Return on assets-33.0%
Return on invested capital-37.0%
Current ratio23.93
Liabilities / assets4.8%
Cash & investments$700.55M
Total debt$4.94M
Net cash (debt)$695.61M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $54.89M $49.00M $42.00M $132.76M $36.52M
Selling and Admin Expenses $11.74M $9.81M $8.53M $29.83M $8.33M
-General & Admin Expense $11.74M $9.81M $8.53M $29.83M $8.33M
Research & Development $43.14M $39.20M $33.47M $102.93M $28.19M
Operating Profit -$54.89M -$49.00M -$42.00M -$132.76M -$36.52M
Net Non-Operating Interest Income (Expense) $3.76M $3.45M $2.69M $12.82M $2.68M
Non-Operating Interest Income $3.76M $3.45M $2.69M $12.82M $2.68M
Pretax Profit -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Net Profit -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Profit from Continuing Operations -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Net Income to Parent Company -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Net Income to Common Stockholders -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Basic EPS -$0.74 -$0.69 -$0.64 -$2.01 -$0.57
Diluted EPS -$0.74 -$0.69 -$0.64 -$2.01 -$0.57

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $727.53M $383.36M $412.04M $282.61M $282.61M
Total Current Assets $711.62M $366.97M $394.61M $265.45M $265.45M
Cash and Cash Equivalents & Short-Term Investments $700.55M $353.94M $383.47M $256.00M $256.00M
-Cash and Cash Equivalents $456.02M $73.84M $84.96M $77.39M $77.39M
-Short Term Investments $244.53M $280.11M $298.51M $178.62M $178.62M
Other Current Assets $11.07M $13.02M $11.15M $9.45M $9.45M
Total Non-Current Assets $15.91M $16.40M $17.43M $17.16M $17.16M
Net PPE $6.26M $6.48M $6.66M $6.89M $6.89M
-Gross PPE $6.26M $6.48M $6.66M $6.89M $6.89M
Other Non-Current Assets $9.65M $9.91M $10.77M $10.27M $10.27M
Total Liabilities $34.68M $29.70M $24.47M $23.43M $23.43M
Total Current Liabilities $29.74M $24.62M $19.26M $18.09M $18.09M
Payables $3.30M $2.33M $3.64M $1.18M $1.18M
-Accounts Payable $3.30M $2.33M $3.64M $1.18M $1.18M
Current Accrued Expenses $25.92M $21.78M $15.13M $16.44M $16.44M
Short-Term Debt and Capital Lease Obligation $521,000.00 $504,000.00 $488,000.00 $472,000.00 $472,000.00
-Current Capital Lease Obligation $521,000.00 $504,000.00 $488,000.00 $472,000.00 $472,000.00
Total Non-Current Liabilities $4.94M $5.08M $5.21M $5.34M $5.34M
Long Term Debt and Capital Lease Obligation $4.94M $5.08M $5.21M $5.34M $5.34M
-Long Term Capital Lease Obligation $4.94M $5.08M $5.21M $5.34M $5.34M
Total Equity $692.84M $353.66M $387.58M $259.18M $259.18M
Stockholders' Equity $692.84M $353.66M $387.58M $259.18M $259.18M
Capital Stock $7,000.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
-Common Stock $7,000.00 $0.00 $0.00 $0.00 $0.00
-Preferred Stock $0.00 $6,000.00 $6,000.00 $5,000.00 $5,000.00
Additional Paid-In Capital $1.20B $810.36M $798.03M $630.04M $630.04M
Retained Earnings -$507.24M -$456.12M -$410.56M -$371.26M -$371.26M
Gains/Losses Not Affecting Retained Earnings -$1.28M -$580,000.00 $107,000.00 $393,000.00 $393,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$32.21M -$31.08M -$32.57M -$95.14M -$23.62M
Net cash flow from continuing operations -$32.21M -$31.08M -$32.57M -$95.14M -$23.62M
Net Income from Continuing Operations -$51.12M -$45.56M -$39.31M -$119.95M -$33.83M
Depreciation & Depletion & Amortization $130,000.00 $138,000.00 $138,000.00 $546,000.00 $132,000.00
Change in Working Capital $6.76M $4.32M -$1.23M -$1.63M $2.58M
-Change in Prepaid Assets $2.22M -$1.02M -$2.44M -$5.08M $404,000.00
-Change in Payables and Accrued Expense $4.53M $5.32M $1.20M $3.37M $2.16M
-Change In Other Working Capital $14,000.00 $17,000.00 $17,000.00 $83,000.00 $17,000.00
Net cash flow from investing $34.92M $17.85M -$120.24M $72.46M $34.38M
Net Cash Flow from Continuing Investing Activities $34.92M $17.85M -$120.24M $72.46M $34.38M
Net PPE Purchase and Sale -$90,000.00 -$66,000.00 -$88,000.00 -$141,000.00 -$57,000.00
Net Investment Purchase and Sale $35.01M $17.92M -$120.16M $72.60M $34.43M
Financing Cash Flow $379.47M $2.10M $160.38M $8.10M $4.68M
Net Cash Flow from Continuing Financing Activities $379.47M $2.10M $160.38M $8.10M $4.68M
Net Common Stock Issuance $376.80M $0.00 $147.85M $0.00 $0.00
Proceeds from Stock Option Exercised $2.68M $2.10M $12.53M $8.10M $4.68M
Ending Cash Balance $457.02M $74.84M $85.96M $78.39M $78.39M
Net Change in Cash $382.18M -$11.12M $7.57M -$14.58M $15.44M
Beginning Cash Balance $74.84M $85.96M $78.39M $92.97M $62.95M
Free Cash Flow -$32.30M -$31.14M -$32.66M -$95.28M -$23.68M

Discussion

No comments yet — be the first to weigh in on TYRA.

Sign in to join the discussion.

Scroll to Top